Background: Chinese herbal medicine (CHM) is a common complementary therapy used by patients with cancer for reduction of chemotherapy-induced toxic effects. This study applied the highest standard of clinical trial methodology to examine the role of CHM in reducing chemotherapy-induced toxicity, while maintaining a tailored approach to therapy.
introduction
Complementary and alternative medicine (CAM) is used by an increasing number of cancer patients [1] [2] [3] [4] . A study from the M.D. Anderson Cancer Center showed that 83.3% of outpatients had used at least one CAM approach and 62.6% had used herbs [5] . The reasons cited for using CAM included immunomodulation, survival prolongation, quality of life (QoL), and reduction of treatment-related toxic effects [3, 5] . Chinese herbal medicine (CHM) is a popular form of CAM in China [6, 7] and its popularity outside China is also undeniable [8] .
The practice of CHM involves selecting a combination of herbal or botanical items for treatment of varying body conditions [9] . The belief that CHM may reduce cancer therapyinduced toxicity is prevalent in China and throughout Asia [7] , but only limited scientific information is available. Two small comparative studies from Japan indicated CHM to be effective in reduction of chemotherapy-induced muscle pain and diarrhea [10, 11] . Both studies focused on a fixed combination of herbal extracts but failed to address the essence of CHM on the dynamic interaction between changing body conditions. Conventional Western medicine is founded on a structured concept with fixed quantification, thus all scientific facts should be evidence based. CHM is fundamentally different. Randomized controlled study is the most rigorous methodology for clinical research and usually involves a standardized therapeutic agent for a homogenous population with clearly defined outcome variables. In contrast, CHM is a nonstandardized entity that can vary over time and between patients. The clinical trial methodology for CHM borrows from the pragmatic trial design rationale, but must be able to capture the essence of CHM and comply with the high ethical and scientific standards of traditional Western medicine. In this study, we aimed to examine the role of CHM as complementary therapy for patients receiving adjuvant chemotherapy. The basic principles of the study design, data management, monitoring, and analysis were conducted according to the Good Clinical Practice Guideline [12] . The study end points were also quantified according to standardized international scales. The intervention was, however, designed in accordance with a true CHM practice that provides variable combinations of herbs according to the condition of individual patients.
patients and methods
The aim of this double-blind placebo-controlled randomized trial was to compare the efficacy of toxicity reduction of CHM with placebo in patients receiving adjuvant chemotherapy. The primary end points were hematologic and non-hematologic toxic effects. Secondary end points included QoL during therapy, treatment compliance, dose intensity, and tumor recurrence rate. The study was approved by the Clinical Research Ethics Committee of The Chinese University of Hong Kong, and written informed consent was obtained from all patients before trial entry. Patients who declined consent to the trial received adjuvant systemic chemotherapy according to standard practice.
entry and exclusion criteria
Consecutive postoperative patients with histologically confirmed breast or colon cancer requiring adjuvant chemotherapy were assessed for eligibility from March 2000 to February 2004. The inclusion criteria were age at least 18 years, Eastern Cooperative Oncology Group (ECOG) performance status of two or less, no prior chemotherapy, and normal hematological function with a total neutrophil count >1.5 · 10 9 /l and platelets >100 · 10 9 /l. The criteria for liver and renal function included total bilirubin less than or equal to twice the upper limits of normal (ULN), alanine transaminase less than or equal to three times ULN, and serum creatinine £1.5 times ULN. Patients who required concurrent radiotherapy or were unable to comply with daily oral medication were excluded. Other exclusion criteria included evidence of distant metastasis, substantial concurrent medical illness, prior chemotherapy, and, for female patients, being pregnant or breast-feeding. metoclopramide and dexamethasone was given as required. Patients in both groups were prescribed oral metoclopramide 10 mg every 4 h, as required. Dose intensity was defined as the total dose of cytotoxic drugs administered during the four cycles of AC or six cycles of FUFA [13] . The time interval was defined as the interval in weeks from day 1 of the first cycle of chemotherapy to day 21 and day 28 of the last cycle of AC and FUFA, respectively. For patients who received fewer than the intended number of cycles of chemotherapy, the treatment duration was calculated on the basis of the projected interval.
adjuvant chemotherapy

treatment groups
Patients who were eligible for adjuvant chemotherapy were routinely screened. Consented patients were randomly assigned to one of three qualified Chinese herbalists. All the herbalists had completed university training and were licenced to practice CHM in China and Hong Kong. Their experience in CHM practice ranged from 15 to 18 years. Each herbalist practiced CHM according to his own training and experience and there was no direct contact or discussion between the herbalists.
For the purpose of this study, we setup a CHM clinic in our cancer center so that the patients' records could be available for the herbalists. The colocation within a cancer center is quite unusual for Hong Kong although the integrative approach is commonplace in Mainland China. On days 1 and 14 of each cycle of chemotherapy, the herbalist evaluated the patients according to the principles of CHM and documented the findings on a case report form. According to the patient's condition, the herbalist prescribed a combination of single-itemized herbs from the stock of commonly used herbs. The patients took the prescription form to a separate room staffed by a technician who randomized each patient to receive either the prescribed herbal combination or placebo packages with corresponding serial number and dispensed accordingly. A 14-day supply of the prescribed combination was dispensed at each clinic visit. Each patient was responsible to completing logbook for each day's consumption.
Two hundred and twenty-five types of the commonly used herbs were stocked in packaged form (Appendix). Each package contained 3-10 g of water-soluble herbal granules that were manufactured at a Good Manufacture Practice standard facility (E-Fong Ltd, Guangzhou, China). Individual herb was boiled in water according to the traditional method of herbal tea preparation. The liquid extract was dehydrated by the nebulization dehydration method, quantified in dry weight, and stored in air-free foil packages ( Figure 1 ). Each package was labeled with a serial number. The prescription form comprised the stock list with both the name and serial number. Random samples of the herbal granule packages were submitted to the Laboratory Testing and Development Services at the Institute of Chinese Medicine, The Chinese University of Hong Kong, for heavy metals analyses, organochlorine pesticide determination, organophosphorus pesticide determination, and microbial evaluation. All packages were within the normal limits set by the local regulatory authority. The raw materials for the placebo included Chinese Puer tea (Camellia amellia sinensis var assamica), black bean paste (Semen Sojae Praeparatum), malt sugar (Fructus Hordei Germinatus), food color, and artificial flavor. It is difficult to define a pure placebo in CHM where all natural substances are potentially therapeutic. We have chosen these substances for their similarity in smell, taste, and appearance to a typical herbal tea. Camellia sinensis is known to have anticarcinogenic and chemopreventive effect [14, 15] , while Semen Sojae Praeparatum and Fructus Herdei Germinatus are used in CHM for reduction of food stagnation in stomach. To improve the authenticity, seven varieties of flavors and colors were created. The placebo packages were randomly filled with one of the seven varieties of nontherapeutic granules and were labeled with a serial number matching the therapeutic packages. The placebo and therapeutic packages were stored in different cabinets and only the dispensing technician knew the contents of the packages. Patients were stratified according to the chemotherapy regimens. The statistician generated the randomization list by the stratified permuted block method and programmed the list in a designated computer inside the dispensing room. The dispensing technician and the data monitoring committee were the only people with access to the randomization list and the contents of each prescription.
end point evaluation
Clinical evaluation at enrollment included a full medical history, physical examination, and assessment for ECOG performance status. Laboratory investigation included complete blood count, serum electrolytes, serum creatinine, liver function test, hepatitis B serology, prothrombin time, International Normalized Ratio (INR), and urinalysis. All patients had full staging radiological work-up according to the institutional protocol before enrollment; only chest X-ray was repeated before randomization. The primary end point of the study was chemotherapy-induced toxicity graded according to the National Cancer Institute Common Toxicity Criteria Version 2 (CTC-V2). Complete blood count, renal, and liver function tests were repeated at baseline and on day 1 of each cycle of chemotherapy. The nadir blood count was done on day 10 of the chemotherapy cycle for patients with breast cancer and on day 15 of the chemotherapy cycle for patients with colon cancer. Subjective assessment of non-hematologic toxicity was carried out on day 1 of each chemotherapy cycle. QoL was measured by the European Organization for Research and Treatment of Cancer (EORTC) core questions on the Quality of Life Questionnaire version 2 (QLQ-C30) [16] . The validated official Chinese translation was adopted [17] . This selfadministered questionnaire was completed by the patients at baseline, on day 1 of each cycle of chemotherapy, and at follow-up 4 months after treatment. Compliance with CHM was evaluated using the record on the patients' logbooks.
statistical design and analysis
Sample size was calculated on the basis that 40% of patients would develop severe toxicity (CTC-V2 grade 3 or more) from adjuvant chemotherapy. Using the two-sided 5% level test to have 80% power of detecting a 20% decrease in a single toxicity 164 patients were required for the study. Considering that patients may experience one or more toxicity during chemotherapy, five common toxic effects were arbitrarily selected for the purpose of sample size estimation. To have 80% power of detecting a 20% difference in at least one of the five toxic effects, the sample size was calculated to be 234 after accounting for multiple comparisons.
Outcomes of toxicity, treatment compliance, and QoL were analyzed using Chi-square and Fisher's exact tests. All P values were two-tailed and the a level of significance was set at 0.05. Logistic regression analysis was used to assess and control for potential prognostic factors. Data are presented according to an intention-to-treat principle, in which patients who withdrew from the trial were recorded as having worsened (if appropriate) for categorical items only.
interim analysis
A formal interim analysis was undertaken by the Data Safety Monitoring Committee on 18 February 2004 when data from 50% of the target accrual became available. The committee found the rate of accrual to be slower than expected. The main reasons for the slow accrual were patients' lack of interest in participating in a placebo-controlled study and their preference of receiving true CHM. At the interim analysis, there was no significant difference in severe toxicity (CTC-V2 grade 3 or above) between the two groups. Despite the small difference in less severe (CTC-V2 grade 2) nonhematological toxicity, the committee concluded that the study would be difficult to continue and recommended early termination.
results
study population
One hundred and twenty patients with resected breast or colon cancer were enrolled in the study, and 60 patients were randomly assigned to each group (Figure 2) . Eight patients refused to use the study herbal packages and one patient was diagnosed with metastatic disease after randomization. The characteristics of the 111 assessable patients are summarized in Table 1 . Age, gender, education level, performance status, tumor type, and chemotherapy regimen were similar in the two groups. The number of patients with stage Ib breast cancer was higher in the group receiving CHM, but the difference was not statistically significant.
adjuvant chemotherapy
Two hundred and ninety cycles of AC were given to the 84 patients with breast cancer (CHM group, 154 cycles; placebo arm, 136 cycles). Treatment compliance rates for the two groups were similar ( Table 2 ). The mean dose intensity for adriamycin Figure 1 . Upper row is the air-free foil packaged Chinese herbal medicine (CHM) granules and lower row is the air-free packaged placebo granules.
original article Annals of Oncology in the CHM and placebo groups were 31.0 mg/week [95% confidence interval (CI) 29.3-32.8 mg/week] and 30.7 mg/week (95% CI 29.8-31.5 mg/week), respectively (P = 0.71), and for cyclophosphamide was 311.2 mg/week (95% CI 294.0-328.4 mg/week) and 306.9 mg/week (95% CI 298.3-315.6 mg/week), respectively (P = 0.66). Twenty-seven patients with colon cancer received 138 cycles of FUFA. More treatment cycles were administered to patients in the placebo group (80 cycles) than to those in the CHM group (58 cycles) (P = 0.48). Mean dose intensity for FUFA for patients in the CHM group was 726.4 mg/week (95% CI 687.6-765.3 mg/week) and 34.3 mg/week (95% CI 32.5-36.1 mg/week), respectively, and for patients in the placebo group was 763.7 mg/week (95% CI 721.5-806.0 mg/ week) and 36.3 mg/week (95% CI 33.6-39.1 mg/week), respectively (P = 0.21).
efficacy of CHM for reducing chemotherapyinduced toxicity
Patients were prescribed individualized combination of herbal extract, and the mean number of packages consumed daily was 25.3 (standard deviation 9.8). Hematologic toxic effects experienced by patients in the CHM and placebo groups are listed in Table 3 . Both groups were associated with a moderate incidence of severe (CTC-V2 grades 3 and 4) neutropenia (52.7% versus 44.7%, P = 0.63) and leukopenia (47.3% versus 32.2%, P = 0.37). Seven patients (CHM four, placebo three; P = 0.68) had febrile neutropenia requiring admission to hospital but all patients had an uneventful recovery. Severe anemia and thrombocytopenia were infrequent and the incidence in the two groups was similar.
Common non-hematologic toxic effects are summarized in Table 4 . Fewer patients in the CHM group experienced moderate (grade 2 or more) nausea than in the placebo group, 
Annals of Oncology original article
and the difference was statistically significant (CHM 16.4% versus placebo 37.6%, P = 0.04). The incidence of moderate vomiting was also less frequent in the CHM group, but this was not statistically significant (CHM 34.6% versus placebo 51.7%, P = 0.22). Anorexia, however, was similar between the two groups (CHM 12.7% versus placebo 10.7%, P = 0.60). There were no significant differences in other non-hematologic toxic effects between the CHM and placebo groups.
quality of life
The change in the score for each domain in the EORTC QLQ-C30 between each cycle of chemotherapy and baseline was compared and there was no significant difference between the CHM and placebo groups. Specifically, the changes in mean score for nausea from AC for cycles one to four from baseline in CHM versus placebo group were 19.9 versus 20.6 (P = 0.84); 21.1 versus 27.8 (P = 0.39); 22.9 versus 20.4 (P = 0.65); and 8.7 and 13.7 (P = 0.19). The magnitude of change of the nausea score was less for patients receiving FUFA than for those receiving AC. The change in scores for cycle one to six of FUFA from baseline was also not statistically significant.
discussion
To the authors' knowledge, this is the first double-blind placebo-controlled randomized trial of the role of CHM in reducing chemotherapy-induced toxicity. CHM was not found to be efficacious for reducing hematologic toxicity associated with adjuvant chemotherapy for breast and colon cancer. The only non-hematologic toxicity that was reduced by CHM was nausea. These results refute the claim made by many patients and herbalists who use CHM as complementary therapy during chemotherapy. Similar to a study by Bensoussan et al. [18] who carried out a double-blind placebo-controlled randomized study of CHM for patients with irritable bowel syndrome, this study adhered to the traditional practice of Chinese medicine that individualized the therapy. Our objective of applying a rigorous clinical trial methodology to traditional practice of CHM, both in terms of individualization and variation over time, is achieved.
Our Chinese herbalists, with university qualification and clinical experience, were at the level that a patient would expect from a Chinese herbal practitioner in the community. One may argue that the lack of improvement in outcomes could merely be a reflection of the herbalists' ability to make a difference. The key feature of traditional Chinese herbal therapy, however, is the high degree of variability between patients, doctors, and the patient's condition at the consultation. The execution of the practice of CHM within this trial was a reasonable representation of the real-life situation.
We found a significant reduction of grade 2 nausea in the CHM group compared with the placebo group. The difference in this toxicity, however, was not reflected by the EORTC QoL questionnaire. The changes in scores from baseline for nausea were similar between the CHM and placebo groups. This may be explained by the sensitivity of the QoL questionnaire to capture subjective differences between grade 1 and grade 2 nausea. The overall incidence of patients experiencing any nausea (grades [1] [2] [3] was similar between the two groups (87.3% in the CHM group and 84.0% in the placebo group). The change in QoL score reflected only the mean experiences of patients who had nausea during treatment. The questionnaire was not designed to distinguish the difference in severity in each subgroup of patients. Other gastrointestinal toxicity such as grade 2 constipation was more common in the placebo group but the difference was not statistically significant.
The majority of our enrolled patients were female because of the diagnosis of breast cancer. We recognize the survival outcomes of breast and colon cancer to be different, so we have only compared the short-term toxicity related to adjuvant chemotherapy. We chose patients on adjuvant chemotherapy as our primary study objects in order to minimize any cancerrelated symptom. Therefore, specific cancer type is not crucial to our study as long as the patient was clinically cancer-free after surgical resection and their general health was fit for chemotherapy.
Our patient population would have little incentive to participate in a placebo-controlled trial on CHM. Many patients have also assumed CHM to be effective and resort to it regularly, so found the placebo-controlled design to be unacceptable. We screened and offered consent to 322 patients but only Treatment groups were compared for differences in incidence of adverse events using Chi-square tests. All statistical tests were two-sided, and P values <0.05 were considered statistically significant. CHM, Chinese herbal medicine; ALT, alanine transaminase. 
